Key facts
- This page summarizes Erick Wayne DeVinney's Form 4 filing for Axogen, Inc. (AXGN).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Jul 2021, 16:16.
Erick Wayne DeVinney - 19 Jul 2021 Form 4 Insider Report for Axogen, Inc. (AXGN)
- Reporting relationship
- VP Peripheral Nerve Science
- Issuer ticker
- AXGN
- Reported as of
- 19 Jul 2021
- Net transaction value
- -$7,526
- SEC form
- 4
- Accepted by SEC
- 21 Jul 2021, 16:16:16 UTC
- Next SEC filing
- 17 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/Erick DeVinney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Erick Wayne DeVinney filed Form 4 for Axogen, Inc. (AXGN) on 21 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$7,526.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXGN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,580
- Change %
- +2%
- Price
- $0.000000
- Shares after
- 80,818
- Date
- 19 Jul 2021
- Ownership
- Direct
- Footnotes
- F1
AXGN
transaction
Common Stock
Tax liability
- Transaction value
- $7,526
- Shares
- -392
- Change %
- -0.49%
- Price
- $19.20
- Shares after
- 80,426
- Date
- 20 Jul 2021
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria.
Footnote F2
The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.